Drug Profile
Helicobacter pylori vaccine - Acambis
Latest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator Acambis
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Helicobacter infections
Most Recent Events
- 25 Sep 2008 Acambis has been acquired by sanofi pasteur
- 12 May 2004 Suspended - Phase-II for Helicobacter infections (Injection)
- 12 May 2004 Suspended - Phase-II for Helicobacter infections in Switzerland (PO)